Kite Teams Up with Oxford Biotherapeutics to Develop Cancer Therapies

Oxford Biotherapeutics (OBT) and Gilead Sciences subsidiary Kite have begun a research collaboration to develop potential cell therapies for blood cancer and solid tumors.

The collaboration will see OBT validate five novel oncology drug targets and generate antibodies against them, while Kite and Gilead will have exclusive rights to develop and commercialize therapies based on the targets or antibodies.

OBT will receive an upfront payment and additional payments for reaching discovery, clinical and regulatory goals, as well as royalties on future sales.